Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial
about
Treating Negative Symptoms in Schizophrenia: an UpdateToward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenInducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux.Negative symptoms in schizophrenia.Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Minocycline exacerbates apoptotic neurodegeneration induced by the NMDA receptor antagonist MK-801 in the early postnatal mouse brain.Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning.The promise of biological markers for treatment response in first-episode psychosis: a systematic review.Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data.Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects.Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major DepressionInflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome compositionGlutamate and dopamine in schizophrenia: an update for the 21st centuryMice haploinsufficient for Map2k7, a gene involved in neurodevelopment and risk for schizophrenia, show impaired attention, a vigilance decrement deficit and unstable cognitive processing in an attentional task: impact of minocycline.Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.Drug repurposing and emerging adjunctive treatments for schizophrenia.MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.Improving Current Treatments for Schizophrenia.Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia.Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia.Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes.Neuropsychiatric Effects of Antimicrobial Agents.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment.A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.Modulating Neuroinflammation to Treat Neuropsychiatric Disorders.Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: A historical cohort study.Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia.A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.Autoimmune phenotypes in schizophrenia reveal novel treatment targets.Altered Serum Tumor Necrosis Factor and Interleukin-1β in First-Episode Drug-Naive and Chronic Schizophrenia.The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trialMinocycline as adjunct therapy for a male patient with deficit schizophreniaEfficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
P2860
Q26744805-CABA76D0-24AC-493B-817C-D69856A5C8FBQ26749972-42C65464-67CF-4DA5-A6F7-BC6DCDD67A16Q27308077-78BC0F9F-20D8-4380-A76A-926563DC747CQ33820512-E077C72D-B00A-49CE-BCD6-046245BB9C43Q34432085-24CA205F-343A-4003-80D3-A02931AD7097Q34674045-60B78D8A-17D9-4E0D-AB99-F3A50894FC11Q34677643-6EAE10FB-B736-403A-B9A7-E949EBDA0CE0Q35369988-D8CA3C03-844B-4005-878E-CCB33B8CA1E5Q35450483-77368BA5-5486-4D92-8DF8-0CD2EB6E4DBCQ35591134-D3D66B4D-4C7B-45DB-9EB2-1C149FC11232Q35798084-640FF070-546F-40B6-B815-89FB140F5863Q36307016-F4891DFD-25F7-4F0F-B001-6E0DB2B578DFQ36932860-EFE2474E-672E-473E-91B8-CEE26DFC03E8Q36992322-5FE32699-3617-4622-B189-07F53FACC6D1Q37547506-B8A2FF01-16AD-40ED-AD52-A43813EA5CD1Q37662441-2E3174EB-A6BE-4F07-B8FF-EED1A076C00BQ38268878-01E671A8-3662-4EE3-8E8E-BDAB98D89700Q38402659-4BE5EA91-BBD8-4B56-AC74-075627DA34BDQ38417631-1EDEE506-BC98-47BB-B7B5-33A286EA2416Q38622769-13527A00-0046-4B50-AF8C-746F141D75CCQ38955513-D7DFA74E-4A9C-4AD9-B8D0-F2A467760F5EQ38970065-721FE7A3-0792-4BE6-8AFB-DB793AC327CAQ39050960-6B195C66-DC00-4B99-BB70-43903DE2E770Q39064271-C05280BE-0C0A-42D8-AA27-8267A8A64E10Q39135986-455D5C43-13BD-4C0A-BB52-739CCCD67B37Q39233330-02940C5D-2B49-406D-89C1-EBECDD1D4A8CQ41173167-6E7CA6DB-A308-4E34-B622-ECD86674B203Q45074171-28A03DE3-1917-4BCB-A4FD-3AB68CF7F8CEQ47140966-903E9E6E-43E9-4A20-95B1-70AEA4D64FEFQ47352196-38437DE7-247B-47E9-8116-BBBB3DDC1E8CQ47406216-FEE6F34E-A628-4862-8F7E-1A6C521B9682Q47861374-B8F7F2E1-6E0E-4F8B-8335-DA2E44E533B1Q54217096-0D53C270-C6A4-49EC-80FA-B79BBF73F342Q55438770-3B455B1B-C163-4FB7-9200-B0EF3D276471Q57471756-D2FBDFC6-3FC6-4273-BD1F-7347510137A2Q57815583-246E6709-B671-4523-84CD-67247F8C3C69Q58561523-F941F4A7-83E3-4812-9960-FC07F2FBEB9A
P2860
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Minocycline supplementation fo ...... , randomized, controlled trial
@ast
Minocycline supplementation fo ...... , randomized, controlled trial
@en
Minocycline supplementation fo ...... , randomized, controlled trial
@nl
type
label
Minocycline supplementation fo ...... , randomized, controlled trial
@ast
Minocycline supplementation fo ...... , randomized, controlled trial
@en
Minocycline supplementation fo ...... , randomized, controlled trial
@nl
prefLabel
Minocycline supplementation fo ...... , randomized, controlled trial
@ast
Minocycline supplementation fo ...... , randomized, controlled trial
@en
Minocycline supplementation fo ...... , randomized, controlled trial
@nl
P2093
P3181
P1476
Minocycline supplementation fo ...... , randomized, controlled trial
@en
P2093
Bingkui Zhang
Jianjun Ou
Jingping Zhao
Junwei Yang
Limei Zhang
Rengrong Wu
Shuyun Yang
P304
P3181
P356
10.1016/J.SCHRES.2014.01.011
P407
P577
2014-03-01T00:00:00Z